Ignite Creation Date:
2025-12-24 @ 3:25 PM
Ignite Modification Date:
2026-02-25 @ 8:11 PM
Study NCT ID:
NCT03070392
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-08-01
First Post:
2017-02-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Sponsor:
Immunocore Ltd
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Uveal Melanoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Melanoma | View |
| None | Uveal Cancer | View |
| None | IMCgp100 | View |
| None | Immunotherapy | View |
| None | Tebentafusp | View |
| None | Ocular Melanoma | View |
| None | Eye Melanoma | View |
| None | Uveal Melanoma | View |
| None | Gp100 | View |
| None | TCR | View |
| None | Dacarbazine | View |
| None | Ipilimumab | View |
| None | Pembrolizumab | View |
| None | Bispecific T cell receptor fusion protein | View |
| None | ImmTAC | View |
| None | Immune mobilizing monoclonal T cell receptor against cancer | View |
| None | Kimmtrak | View |